Esophageal Cancer News and Research

RSS

Esophageal Cancer is cancer that forms in tissues lining the esophagus (the muscular tube through which food passes from the throat to the stomach). Two types of esophageal cancer are squamous cell carcinoma (cancer that begins in flat cells lining the esophagus) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids).

Early detection of PGAP may reduce mortality rate

Gastrectomy is commonly performed for both benign and malignant lesions. Although the incidence of post-gastrectomy acute pancreatitis (PGAP) is low compared to other well-recognized post-operative complications, it has been reported to be associated with a high mortality rate.

19 Oct 2009

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Cell Therapeutics, Inc. announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when given OPAXIO(TM) (paclitaxel poliglumex), a biologically enhanced paclitaxel, when administered in combination with standard cisplatin and concurrent radiation.

1 Oct 2009

SBIR grant from NIH to GenVec for metastatic cancer research

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.

30 Sep 2009

GenVec to receive $2.3M from NIAID for HIV vaccine candidate production

GenVec, Inc. announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), has executed its third option period (year four) under a previously announced, five-year contract with GenVec valued at up to $52 million for the production of HIV vaccines.

26 Sep 2009

Careful follow-up after eradication therapy for peptic ulcer needed

Although it has been demonstrated that Helicobacter pylori causes gastric cancer, it is still controversial that whether H. pylori eradication therapy is effective in primary prevention of gastric cancer. This is especially important for Yamagata Prefecture, a region of Japan with the second highest incidence of gastric cancer in the world.

25 Sep 2009

Research study links cancer to excess body weight

At least 124,000 new cancers in 2008 in Europe may have been caused by excess body weight, according to estimates from a new modelling study. The proportion of cases of new cancers attributable to a body mass index of 25kg/m2 or more were highest among women and in central European countries such as the Czech Republic, Latvia, Slovenia and Bulgaria.

From The University of Manchester 24 Sep 2009

Phase II study of OPAXIO to be revealed

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that data from a Phase II study from Brown University of OPAXIO(TM) (paclitaxel poliglumex) combined with standard cisplatin and concurrent radiation in patients with advanced esophageal cancer will be presented by Dr. Howard Safran in an oral Proffered Papers session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia, Pennsylvania on Thursday, October 1st at 2:35 p.m. (Eastern time).

24 Sep 2009

Study reveals that YAP can be used for the diagnosis of gastric carcinoma

A research team led by Professor Yan Xin, from The Fourth Laboratory of Cancer Institute in China measured the expression of YAP and survivin in normal gastric mucosa, precancerous lesions and gastric carcinoma using an immunohistochemical method to analyze the significance and correlations of the 2 factors with gastric carcinogenesis.

17 Sep 2009

Study: HBV genotype is not linked to hepatocellular carcinoma

Previous studies revealed that HBV genotypes as well as mutations in the core promoter, precore or HBx gene have been shown to have an association with the clinical outcome of liver disease, however, this is still controversial. It is likely that this depends on the HBV genotype distribution in certain region.

17 Sep 2009

NASDAQ Stock Market issues notification letter to GenVec

On September 15, 2009, GenVec, Inc. (Nasdaq: GNVC) received a notice from The NASDAQ Stock Market stating that the minimum bid price of the Company's common stock was below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with Marketplace Rule 5450(a)(5).

17 Sep 2009

Underlying malignancies can cause rebleeding after negative angiography

Acute non-variceal gastrointestinal bleeding accounts for approximately 20% of emergency room visits and 5% of admissions. Although endoscopy has been used as a first-line treatment option in patients with gastrointestinal bleeding, angiographic intervention can be used as a safe diagnostic and treatment method in patients with gastrointestinal bleeding that is refractory to endoscopic treatment.

17 Sep 2009

Learning curve method checks the proficiency level in laparoscopic splenectomy procedures

A research team, led by Dr. Tarik Z. Nursal from the University of Baskent, has investigated the proficiency level reached in laparoscopic splenectomy procedures using the learning curve method. Their study will be published on August 28, 2009 in the World Journal of Gastroenterology.

17 Sep 2009

Multi-detector row computed tomography predicts malignancy of IPMNs

A clinical research article to be published on August 28, 2009 in the World Journal of Gastroenterology addresses the role of multi-detector row computed tomography (MDCT) in predicting malignancy of IPMNs preoperatively. The research team led by Prof. Wang DB from Ruijin Hospital of Shanghai Jiao Tong University School of Medicine recruited a total of 20 patients with pathologically-confirmed IPMNs in their study. Axial MDCT images combined with CT angiography (CTA) and multiplanar volume or curved reformations (MPVR or CR) were preoperatively acquired.

17 Sep 2009

Standard liver volume formula for Chinese adults published

Living donor liver transplantation (LDLT) has been used to alleviate the shortage of available liver donors. Accurate estimation of the standard liver volume (SLV) of the living donor and recipient is crucial. Scholars of different countries established several SLV formulae from clinical data, but which formula was the most accurate for Chinese adults has remained unclear.

17 Sep 2009

Clinical study investigates laboratory and clinical implications of proton pump inhibitor drugs

Fears about the cancer causing effects of the second most prescribed group of drugs in the Western world have been put to rest, following the largest ever study into their use.

10 Sep 2009

Less-invasive, organ-sparing endoscopic therapy for treating early stages of esophageal cancer

Researchers have found that early stage cancers of the esophagus can be treated as effectively by less-invasive, organ-sparing endoscopic therapy as compared to more complex surgical removal of the esophagus, according to a Mayo Clinic study published in the September 2009 issue of Gastroenterology.

2 Sep 2009

Nighttime acid reflux symptoms impair sleep quality

There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Three new studies in Clinical Gastroenterology and Hepatology explore GERD's effect on sleep quality and the health-care system as well as how a widely prescribed sleeping pill may mask the disease.

1 Sep 2009

Genvec to sell 8,000,000 shares to develop its TNFerade clinical program

GenVec, Inc. (Nasdaq: GNVC) announced today that it has entered into a purchase agreement with a single institutional investor for the sale of 8,000,000 shares of its common stock and warrants to purchase 4,000,000 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and 0.50 warrants to purchase one share of common stock at a price of $0.75 per unit. This represents a discount of approximately 8.3% to the closing price of GenVec common stock on August 26, 2009. The warrants have a term of five years and an exercise price of $0.828 per share.

28 Aug 2009

Studies suggest that serrated polyps can be precursors of colon cancers

Serrated colorectal polyps include the subgroups hyperplastic polyps, sessile serrated polyps (also called sessile serrated adenomas), and serrated adenomas. Recent studies have found that serrated polyps share molecular features with a subgroup of colon cancers, leading to the hypothesis that serrated polyps can be precursors of cancer through a hyperplastic polyp to serrated adenoma to cancer sequence.

26 Aug 2009

Duodenal obstruction observed after selective transcatheter arterial embolization for a duodenal diverticular hemorrhage

Ho Jeong and his colleague from Korea presented a case of duodenal obstruction after successful selective transcatheter arterial embolization (TAE) for a duodenal diverticular hemorrhage. Their study will be published on August 14, 2009 in the World Journal of Gastroenterology.

26 Aug 2009